| Literature DB >> 27401645 |
Jung Ki Jo1, Sung Kyu Hong2, Seok Soo Byun2, Homayoun Zargar3, Riccardo Autorino4, Sang Eun Lee5.
Abstract
PURPOSE: To assess the impact of intravesical prostatic protrusion (IPP) on the outcomes of robot-assisted laparoscopic prostatectomy (RALP).Entities:
Keywords: Continence; intravesical prostatic protrusion; robot assisted radical prostatectomy; transrectal ultrasonography
Mesh:
Year: 2016 PMID: 27401645 PMCID: PMC4960380 DOI: 10.3349/ymj.2016.57.5.1145
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Fig. 1Intravesical prostatic protrusion (IPP) under transrectal ultrasound. (A) IPP (Grade 3). (B) No-IPP.
Fig. 2IPP grade: Grade I (A), Grade II (B), Grade III (C), Grade III (transverse plane) (D); C and D are images of same patient. White line shows IPP. IPP, intravesical prostatic protrusion.
Baseline Characteristics of Study Population
| Variables | IPP | Non-IPP | |
|---|---|---|---|
| Patients, n | 180 | 641 | |
| Age (SD) | 66.8 (7.2) | 65.5 (7.0) | 0.03 |
| BMI, kg/m2 (SD) | 23.95 (2.4) | 24.36 (2.9) | 0.079 |
| PSA, ng/mL (SD) | 13.6 (14.1) | 13.1 (19.5) | 0.752 |
| Prostatic volume | 41.7 (16.5) | 34.4 (11.6) | <0.001 |
| TZI | 0.43 (0.14) | 0.40 (0.12) | 0.002 |
| CCI (%) | 0.727* | ||
| 0 | 150 (83.3) | 527 (82.2) | |
| 1 or more | 30 (16.7) | 114 (17.8) | |
| Clinical stage, n (%) | 0.798* | ||
| T1 | 116 (64.4) | 415 (64.7) | |
| T2 | 57 (31.7) | 194 (30.3) | |
| T3 | 7 (3.9) | 32 (5.0) | |
| Biopsy gleason score, n (%) | 0.730* | ||
| ≤6 | 87 (46.0) | 291 (45.4) | |
| 7 | 67 (37.2) | 245 (38.2) | |
| 8-10 | 26 (14.4) | 105 (16.4) | |
| Nerve-sparing status | <0.001* | ||
| Unilateral (Rt.) | 9 (5.0) | 60 (9.4) | |
| Unilateral (Lt.) | 8 (4.4) | 20 (3.1) | |
| Bilateral | 95 (52.8) | 414 (64.6) | |
| Non-nerve sparing | 68 (37.8) | 147 (22.9) | |
| Membranous urethra length, mm (SD) | 12.14 (2.8) | 12.44 (6.7) | 0.563 |
| NCCN risk group | 0.989* | ||
| Low | 49 (27.2) | 178 (27.8) | |
| Intermediate | 81 (45.0) | 287 (44.8) | |
| High | 50 (27.8) | 178 (27.5) |
IPP, Intravesical prostatic protrusion; BMI, body mass index; PSA, prostate specific antigen; CCI, Charlson Comorbidity Index; TZI, transitional zone index (=transional zone volume/total gland volume); NCCN, National Comprehensive Cancer Network.
*Student-t test, chi test.
Correlation of Preoperative IPP and Continence after RALP
| Continence | Incontinence | ||
|---|---|---|---|
| Postoperative 3 months | <0.001 | ||
| Non-IPP | 504 (78.6) | 137 (21.4) | |
| IPP (Grade I) | 20 (33.3) | 40 (66.7) | |
| IPP (Grade II) | 31 (30.4) | 71 (69.6) | |
| IPP (Grade III) | 2 (11.1) | 16 (88.9) | |
| Postoperative 6 months | <0.001 | ||
| Non-IPP | 586 (91.4) | 55 (8.6) | |
| IPP (Grade I) | 35 (58.3) | 25 (41.7) | |
| IPP (Grade II) | 52 (51.0) | 50 (49.0) | |
| IPP (Grade III) | 8 (44.4) | 10 (55.6) | |
| Postoperative 12 months | <0.001 | ||
| Non-IPP | 617 (96.3) | 24 (3.7) | |
| IPP (Grade I) | 51 (85.0) | 9 (15.0) | |
| IPP (Grade II) | 76 (74.5) | 26 (25.5) | |
| IPP (Grade III) | 13 (72.2) | 5 (27.8) |
IPP, intravesical prostatic protrusion; RALP, robot-assisted laparoscopic radical prostatectomy.
Chi test.
Multivariate Analyses for the Identification of Significant Predictor of Postoperative 12 Months Continence in Patients Undergoing RALP
| Multivariate | ||
|---|---|---|
| OR | ||
| Age | 1.068 (1.018-1.121) | 0.007 |
| BMI | 1.083 (0.970-1.210) | 0.157 |
| Prostate volume (TRUS volume) | 1.001 (0.982-1.020) | 0.938 |
| PSA | 1.000 (0.983-1.018) | 0.992 |
| Gleason score | ||
| 6 | Ref. | |
| 7 | 0.805 (0.426-1.519) | 0.502 |
| ≥8 | 1.498 (0.683-3.287) | 0.313 |
| CCI (0 vs. 1 or more) | 0.851 (0.408-1.773) | 0.666 |
| Non-NS vs. NS | 1.295 (0.689-2.434) | 0.422 |
| Non-IPP vs. IPP | 7.614 (4.244-13.663) | <0.001 |
OR, odds ratio; RALP, robot-assisted laparoscopic radical prostatectomy; BMI, body mass index; TRUS, transrectal ultrasound; PSA, prostate specific antigen; CCI, Charlson Comorbidity Index; NS, nerve-sparing; IPP, intravesical prostatic protrusion; TZI, tranzional zone index.
Multivariate analysis including age, BMI, TZI, prostate volume, risk group, CCI, NS status, IPP.
Pathologic Outcomes of Patients According to Group
| Non-IPP | IPP | ||
|---|---|---|---|
| Pathologic gleason | 0.276 | ||
| 6 | 58 (9.0) | 23 (12.8) | |
| 7 | 502 (78.3) | 137 (76.5) | |
| 8 or greater | 81 (12.6) | 19 (10.6) | |
| Pathologic stage | 0.375 | ||
| T2 | 445 (69.4) | 123 (68.7) | |
| T3 | 190 (29.6) | 52 (29.1) | |
| T4 | 6 (0.9) | 4 (2.2) | |
| Extracapsular extension | 188 (29.3) | 54 (30.2) | 0.828 |
| Seminal vesicle invasion | 57 (8.9) | 15 (8.4) | 0.83 |
| Lymph node invasion | 15 (2.3) | 1 (0.6) | 0.239 |
| Positive surgical margin | 184 (28.7) | 45 (25.1) | 0.347 |
IPP, intravesical prostatic protrusion.
GEE Model for the Identification of Significant Predictors of Postoperative Continence in Patients Who Underwent RALP
| Multivariate | ||
|---|---|---|
| OR | ||
| Age | 1.062 (1.034-1.090) | <0.001 |
| BMI | 0.999 (0.944-1.056) | 0.967 |
| Prostate volume (TRUS volume) | 0.993 (0.980-1.005) | 0.233 |
| PSA | 0.991 (0.981-1.002) | 0.113 |
| Gleason score | ||
| 6 | Ref. | |
| 7 | 1.047 (0.738-1.484) | 0.797 |
| ≥8 | 1.468 (0.926-2.327) | 0.103 |
| CCI (0 vs. 1 or more) | 0.969 (0.652-1.439) | 0.875 |
| Postoperative 3 month | Ref. | |
| Postoperative 6 month | 0.342 (0.286-0.408) | <0.001 |
| Postoperative 12 month | 0.118 (0.088-0.158) | <0.001 |
| Non-NS vs. NS | 0.957 (0.656-1.397) | 0.819 |
| Non-IPP vs. IPP | 9.442 (6.583-13.543) | <0.001 |
OR, odds ratio; RALP, robot-assisted laparoscopic radical prostatectomy; BMI, body mass index; TRUS, transrectal ultrasound; PSA, prostate specific antigen; CCI, Charlson Comorbidity Index; NS, nerve-sparing; IPP, intravesical prostatic protrusion; TZI, transitional zone index; GEE, generalized estimating equation.
GEE model including age, BMI, TZI, prostate volume, risk group, CCI, NS status, IPP.
Fig. 3GEE model for postoperative incontinence rates. GEE, generalized estimating equation.